♥ HF Guideline NavigatorESC 2026

5 › 5.1

5.1 Key steps in the diagnosis

Pages 21–24 · open in PDF

Recommendations in this section

  • Class ILevel CIn patients with suspected HF, the following laboratory tests are recommended when screening for comorbidities: full blood count, kidney function (eGFR and UACR), electrolytes, liver function, thyroid function, HbA1c, lipids, and iron status (TSAT and ferritin).
  • Class ILevel CNatriuretic peptide measurement is recommended in patients with suspected HF (interpreted in relation to patient age, obesity, and other factors known to affect natriuretic peptide level).
  • Class ILevel CA 12-lead ECG is recommended in patients with suspected HF.
  • Class ILevel CChest radiography (X-ray) is recommended in patients with suspected HF.
  • Class ILevel CTransthoracic echocardiogram is recommended in patients with suspected HF to confirm the diagnosis, differentiate between HF phenotypes and aid in identifying the underlying aetiology of HF.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 21 · PDF

4.2.1. Asymptomatic left ventricular dysfunction Based on normal reference values of LVEF in adult populationbased samples, LV systolic dysfunction should be considered present if patients are asymptomatic and have an LVEF <50% in the absence of alternative explanations (e.g. athlete’s heart) for both men and women and regardless of age. Treatment with an ACE-I (or ARB if intolerant) if LVEF ≤40% and a beta-blocker if LVEF <50% are recommended to reduce the risk of HF and mortality. The evidence behind these recommendations are derived from the SOLVD-Prevention trial,135,136 which randomized patients with asymptomatic LV systolic dysfunction (LVEF ≤35%) to enalapril or placebo, and the TRACE137 and SAVE138 trials, which randomized patients post-MI with LVEF ≤35%–40% to trandolapril or placebo (TRACE) and captopril vs placebo (SAVE). These studies were conducted in the 1990s and contemporary management of multiple comorbidities (MI, diabetes, CKD) has since changed. One RCT, CAPRICORN, published in 2001, investigated beta-blockers post-MI in patients with LV systolic dysfunction, where patients were randomized to carvedilol or placebo.139 It should be noted that this trial allowed patients to receive intravenous (i.v.) diuretics for acute HF, but excluded those with continuous need for i.v. diuretics, meaning not all had truly asymptomatic LV systolic dysfunction. The hazard ratio (HR) for all-cause mortality was 0.77 [95% confidence interval (CI) 0.60–0.98] in the group receiving carvedilol vs placebo. Additional observational data from SOLVD and SAVE suggested similar improved outcomes with a beta-blocker.140–142 Further, the REVERT trial, which randomized asymptomatic patients with LVEF <40% to metoprolol extended release or placebo, showed that metoprolol reversed LV remodelling.142 The role of these drugs for asymptomatic individuals with mildly reduced LVEF (41%–49%) is not well studied, but their use is reasonable also in this range of LVEF given the shared pathophysiology with more depressed LV systolic function. A meta-analysis of BETAMI–DANBLOCK and REBOOT-CNIC showed a significant reduction in the combined endpoint of mortality, MI and HF with beta-blockers vs placebo in post-MI patients with stage B HF and mildly reduced LVEF.121 Careful follow-up to assess for progressive decline in LVEF is otherwise warranted for patients without treatment. Based on the results of the EPHESUS trial, eplerenone is recommended in patients after MI with LVEF ≤40% and diabetes to reduce the risk of HFH or death.143

4.2.2. Valvular heart disease Prevention of HF in patients with valvular disease should follow the recommendations outlined in the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.9

Recommendations An ACE-I or ARB (if intolerant to ACE-I) is recommended in patients with stage B HF and LVEF ≤40% to reduce the risk of HFH and

death.135–138,144 A beta-blocker is recommended in patients with stage B HF and LVEF <50% to reduce the risk of HFH or death.35,139,140 Eplerenone is recommended in patients with LVEF ≤40% after myocardial infarction with signs of HF or diabetes to reduce the risk of HFH and death.143

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HF, heart failure; HFH, heart failure hospitalization; LVEF, left ventricular ejection fraction. a Class of recommendation. b Level of evidence.

4.3. Risk prediction in patients with established heart failure Several risk scores have been developed to predict HFH and mortality among ambulatory patients with established HF, including e.g. the MAGGIC risk score,77 the Seattle Heart Failure Model,78 and the more recent ESC initiated LIFE-HF79 (HFrEF) and LIFE-Preserved (HFpEF).80 It should be noted that LIFE-HF included patients with LVEF ≤40% and LIFE-Preserved patients with LVEF ≥50%. The ESC scores therefore need to be validated for HFrEF patients in the upper range of LVEF (>40%–49%) and, ideally, in external samples across the entire LVEF spectrum before widespread implementation (see Supplementary data online, Section S1 and Figure S1). Although pharmacological treatments are indicated in patients with established HF regardless of estimated risks (as outlined in Section 6), these risk scores may be helpful in identifying high-risk patients that may benefit from closer follow-up and to facilitate discussions around patient goals of care.

5. Diagnosis of chronic heart failure 5.1. Key steps in the diagnosis of chronic heart failure The failing heart causes a clinical syndrome with a wide array of signs and symptoms, which vary in sensitivity and specificity (Table 7), and none of which are entirely characteristic. The severity of HF symptoms can be classified according to the New York Heart Association (NYHA) functional class (Table 8). Specialist assessment relies on clinical evaluation, the examination of individual risk factors, and previous medical history as well as 12-lead ECG and chest X-ray evaluation. Clinical suspicion should be followed by testing of natriuretic peptides and echocardiography (Figure 4). In the very elderly patients, suspicion should be raised even with an atypical presentation. A recent HFA consensus paper provides a diagnostic framework for general practice and non–cardiology-based physicians.145

4.2. Patients with stage B heart failure

Recommendation Table 2 — Recommendations for stage B heart failure and left ventricular dysfunction (see Evidence Table 16)

(e.g. tetralogy of Fallot, transposition of the great arteries, truncus arteriosus, double-outlet right or left ventricle, with up to 42-fold risk), and severe non-conotruncal defects (e.g. atrioventricular septal defects, single ventricle and hypoplastic left heart syndrome, with up to 21-fold increased risk).131 Conventional HF risk factors (e.g. CAD, hypertension, diabetes, and obesity) are common in patients with congenital heart disease and contribute significantly to HF risk.132–134 Careful attention to riskfactor modification is warranted as they are likely to contribute to the risk of developing HF.

Page 22 · PDF

22 Symptoms and signs of heart failure

Table 8 New York Heart Association functional classification based on severity of symptoms and physical activity

Elevated jugular venous pressure

Paroxysmal nocturnal dyspnoea

Third heart sound (gallop rhythm)

Reduced exercise tolerance

Laterally displaced apical impulse

Severity of symptoms and physical activity

No limitation of physical activity. Ordinary physical activity does not cause undue breathlessness, fatigue, or palpitations.

Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue, or palpitations.

Fatigue, tiredness, increased

time to recover after exercise

Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity results in undue breathlessness, fatigue, or palpitations.

Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any

Weight loss (in advanced HF)

physical activity is undertaken, discomfort is

Confusion (especially in the

Peripheral oedema (ankle, sacral,

NYHA, New York Heart Association.

Tachypnoea Cheyne–Stokes respiration Hepatomegaly Cold extremities Oliguria Narrow pulse pressure

HF, heart failure. a Elderly patients may present with more atypical symptoms of HF. b Breathlessness on bending forward/flexing the body.

5.1.1. Natriuretic peptides Adverse clinical events often occur soon after a new presentation of HF in the community; therefore, timely diagnosis and initiation of treatment are essential. Natriuretic peptide testing is recommended to support the diagnosis of HF and improves efficiency by avoiding unnecessary echocardiography and/or specialist assessment.146–150 N-terminal pro-B-type natriuretic peptide (NT-proBNP) is the most widely used natriuretic peptide in the management of HF in Europe and has two key advantages: better stability at room temperature, enabling reliable testing in both hospital and community settings; and unaltered results despite treatment with ARNIs, which affect B-type natriuretic peptide (BNP) degradation.149,150 However, testing for NT-proBNP is not universally available, and some regions employ BNP or mid-regional pro-atrial natriuretic peptide (MR-proANP) testing. The 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure recommended a single natriuretic

peptide threshold to ‘rule out’ HF (<125 pg/mL for NT-proBNP, <35 pg/mL; for BNP, <40 pg/mL; for MR-proANP). Single natriuretic peptide rule-out thresholds have the advantage of simplicity; however, natriuretic peptide levels are strongly related to age and lack specificity in older people.151 More than 75% of a healthy population >80 years were found to exceed the 125 pg/mL NT-proBNP threshold.152–156 The HFA-ESC consensus statement on NT-proBNP testing recommends introducing age-related thresholds determined from the 95th percentile of the Generation Scotland cohort to improve specificity and reduce unnecessary demand on echocardiography and HF services.157 The suggested age-adjusted NT-proBNP levels, above which HF is ‘likely’ in the outpatient setting, were ≥125 pg/mL for those aged <50 years, ≥250 pg/mL between 50 and 75 years, and ≥500 pg/mL over 75 years.151,157 Currently there are insufficient data for determining age-specific BNP cut-offs. For the diagnosis of HFpEF, natriuretic peptide interpretation may be challenging as a variety of conditions associated with HFpEF affect natriuretic peptide levels (Table 9).158 Especially obesity is associated with lower cut-off values for natriuretic peptides, and caution is advised when interpreting natriuretic peptide levels in obese patients.158–160 Reduced kidney function has been shown to be associated with higher NT-proBNP levels, although NT-proBNP measurements should not be disregarded in the setting of kidney dysfunction.161,162 Furthermore, many other factors can elevate natriuretic peptide levels (Table 9). Clinicians must consider these factors in conjunction with clinical assessment and investigation findings when interpreting natriuretic peptide measurements; however, the higher the natriuretic peptide level the greater the likelihood of HF as the diagnosis. Natriuretic peptides also provide important prognostic information, enabling rapid triage of high-risk patients. Primary care data from England demonstrate that patients with HF and NT-proBNP levels exceeding 2000 pg/mL exhibit a two-fold increased risk of early HFH. Accordingly, expedited specialist assessment of this high-risk cohort is warranted.163

Page 23 · PDF

Figure 4 Diagnostic algorithm for chronic heart failure presenting in the outpatient or community setting. BNP, B-type natriuretic peptide; CXR, chest X-ray; ECG, electrocardiogram; HbA1c, glycated haemoglobin; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; POCUS, point-of-care ultrasound; TSAT, transferrin saturation; UACR, urine albumin-to-creatinine ratio. a Full blood count, kidney function, electrolytes, UACR, liver function, thyroid function, HbA1c, lipids, and iron status (TSAT and ferritin). b Examination by POCUS may aid in diagnosis although echocardiography is recommended. cNatriuretic peptides may be false low in certain settings (Table 9). dPreferable performed within 2 weeks if NT-proBNP >2000 pg/mL.

Page 24 · PDF

required in the assessment of kidney function.164 UACR is independent of glomerular filtration rate (GFR), and severe albuminuria (grade A3) may be present despite GFR ≥90 mL/min/ 1.73 m2. UACR has strong independent prognostic value for patients with HF.165,166 Albuminuria is a potentially treatable and reversible disorder, amenable to medications also used in HF, including ACE-Is/ARNIs/ARBs, MRAs, and SGLT2-Is.167

Table 9 Causes for increase or decrease in natriuretic peptide levels Causes for increased natriuretic peptide levels Acute coronary syndrome Advanced agea Atrial fibrillation Cardiac contusion Critical illness Female sex Kidney dysfunction

LV hypertrophy Myocarditis

In patients with suspected HF, the following laboratory tests are recommended when

screening for comorbidities: full blood count,

kidney function (eGFR and UACR), electrolytes, liver function, thyroid function, HbA1c, lipids,

Pulmonary embolism Pulmonary hypertension

and iron status (TSAT and ferritin).168

Natriuretic peptide measurement is (interpreted in relation to patient age, obesity, and other factors known to affect natriuretic

Severe endocrine dysfunction Severe infections (including pneumonia and sepsis)

A 12-lead ECG is recommended in patients with

Severe metabolic acidosis and diabetic ketoacidosis

Chest radiography (X-ray) is recommended in

patients with suspected HF.

in patients with suspected HF to confirm the

African ancestry ARNI /ACE-I/ARB

diagnosis, differentiate between HF phenotypes and aid in identifying the underlying aetiology of

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; RV, right ventricular; SGLT2-I, sodium–glucose co-transporter 2 inhibitor. a See Figure 4. b ARNI may raise BNP levels.

5.1.2. Other laboratory tests Basic investigations, such as serum urea and electrolytes, creatinine, full blood count, glycated haemoglobin, lipids, iron status [transferrin saturation (TSAT) and ferritin], liver and thyroid function tests, are recommended to assess for and evaluate comorbidities, to provide prognostic information, and to guide potential therapy. Urine albumin-to-creatinine ratio (UACR) has been added to the initial baseline investigations, because the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines advise that both estimated glomerular filtration rate (eGFR) and UACR (graded A1, <30 mg/g; A2, 30–300 mg/g; A3, >300 mg/g) are

ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TSAT, transferrin saturation; UACR, urine albumin-to-creatinine ratio. a Class of recommendation. b Level of evidence. c See Figure 4 for age-adjusted cut-offs for NT-proBNP levels, and Table 9 for factors affecting natriuretic peptide levels.

5.2. Heart failure phenotypes based on left ventricular ejection fraction Echocardiography provides evaluations of both systolic and diastolic function and valvular function and enables the distinction between HF (stage C) phenotypes based on LVEF.

5.2.1. Heart failure with reduced ejection fraction The diagnosis of HFrEF requires the following criteria: (i) Presence of current or prior symptoms and/or signs of HF (Table 7) (ii) LVEF <50%. Elevated natriuretic peptides strongly support the diagnosis of HFrEF in the presence of symptoms, and may aid in the

Transthoracic echocardiogram is recommended

Causes for decreased natriuretic peptide levels

peptide levelc).146–148,151–153,169

recommended in patients with suspected HF

Recommendation Table 3 — Recommendations for diagnostic investigations in all patients with suspected heart failure (see Evidence Tables 17–19)